While the exact role of Urotensin-II in human cardiovascular disease remains unclear, the development of its receptor modulators may provide therapeutic potential and aid in further characterization.
Answers are grounded in this paper and cite their sources.
Urotensin-II role in human CVD remains unclear; leaves open whether receptor modulators may aid characterization or offer therapeutic potential.
Urotensin-II (U-II) potently contracts some large isolated blood vessels and cardiac tissue. However, the maximum effects on human blood vessels and heart are relatively small. U-II dilates human resistance arteries. It markedly decreased myocardial function and increased vascular resistance in cynomolgus monkeys, but the major effects of U-II have not been observed in healthy humans. A major role for U-II in human cardiovascular disease has not been clearly established despite studies in patients with coronary artery disease, heart failure, essential hypertension and diabetes. Peptide and non-peptide agonists and antagonists of the U-II receptor are being developed and will be useful in the characterisation of the effects of U-II, and may have some therapeutic potential.
No takes yet. Share an insight, caveat, or question.
Sheila A Doggrell (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: